Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01363024 · ClinicalTrials.gov registry record · Phase 1

Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors

A Phase 1 study of Solid Tumor, sponsored by Genentech.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target
5
Study locations

NCT01363024 is a Phase 1 study of Solid Tumor that has completed, run by Genentech. The registered enrollment target is 24 participants, below the 222-participant average among 196 other Solid Tumor trials with a reported enrollment target (89% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01363024, a Phase 1 study of Solid Tumor, has completed, sponsored by Genentech.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target
5
Study locations

Study Summary

This is a multicenter, open-label, dose-escalation study to assess the safety, tolerability and Pharmacokinetics of MGFR1877S.

Conditions Studied

Solid Tumor

Interventions

  • DRUG MFGR1877S

Study Locations (5)

Arizona

  • - Scottsdale

California

  • - Santa Monica

Colorado

  • - Aurora

Illinois

  • - Chicago

Tennessee

  • - Nashville

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2011-08
Est. Completion 2013-03
Phase Phase 1

Sponsor

Genentech

332 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01363024

The ClinicalTrials.gov registry entry for NCT01363024 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 222-participant average among 196 other Solid Tumor trials with a reported enrollment target (89% lower). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which MFGR1877S is the first listed.

NCT01363024 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Arizona, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT01363024 about?

NCT01363024 is a clinical study titled "Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors". This is a multicenter, open-label, dose-escalation study to assess the safety, tolerability and Pharmacokinetics of MGFR1877S.

What is the current status of trial NCT01363024?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2011-08. Estimated completion is 2013-03.

What conditions does trial NCT01363024 study?

This clinical trial studies the following conditions: Solid Tumor.

What interventions are being tested in trial NCT01363024?

The interventions under investigation include: MFGR1877S (DRUG).

Who is sponsoring clinical trial NCT01363024?

This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01363024 being conducted?

This trial has 5 study locations across Arizona, California, Colorado, Illinois, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumor

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.